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significantly higher in the wound blush-positive group than in the wound blush-
negative group, and remained so for at least 3 years after the EVT (96.4% vs. 56.8%,
P<0.001).
Conclusion: Wound blush as an angiographic endpoint in EVT may be a novel
predictor of limb salvage in patients with CLI.
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Lesions
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Background: The optimal endovascular treatment for complex femoropopliteal (FP)
disease is unknown. Percutaneous transluminal angioplasty (PTA) carries a high rate
of restenosis while nitinol stent implantation can result in fractures. The Viabahn stent
graft (Gore Medical; Flagstaff, AZ) was developed to reduce restenosis and increase
overall flexibility. The purpose of this study was to evaluate the efficacy of the Viabahn
stent graft in complex FP disease.
Methods: We evaluated 57 limbs in 48 patients receiving Viabahn stent grafts. Patient
demographics, comorbidites, and procedural details were collected. Outcomes included
primary patency, assisted primary patency, secondary patency, and pre- and
postprocedural ankle brachial index and Rutherford classification.
Results: The study group consisted primarily of TASC II C (n=27;47%) and D
(n=24;42%) lesions (mean age 74.5; male sex=68%). Indications for revascularization
were lifestyle limiting claudication (70.2%), critical limb ischemia (28.1%), and
popliteal aneurysm exclusion (8.8%). Twenty-six patients (46%) had undergone
previous PTA, and 8 patients (14%) had undergone previous peripheral bypass. The
average graft length was 25.4 cm, with an average of 2.1 grafts implanted. There were
no periprocedural complications. Follow-up was available for 53 limbs (93%) with a
mean follow-up of 8.5 months (range 1-22). Average ABI improved from 0.59 to 0.96.
Eight limbs (15.1%) experienced restenosis and 5 limbs (9.4%) had an occlusion. The
primary patency rate for the mean follow-up time was 75.5%. Assisted primary patency
was 90.6% (all restenotic limbs successfully revascularized) and secondary patency
was 96.2% (3 of 5 occlusions with restored patency). At follow-up, 42 patients (80.8%)
were symptom free, 8 patients (15.4%) had Rutherford Class 2-3 symptoms, and 1
patient (1.9%) had critical limb ischemia.
Conclusion: Viabahn stent grafting is a safe and effective option for patients with
complex FP lesions. Patency rates are favorable despite the complexity of disease.
Restenosis and occlusion, while uncommon, can occur which mandates close follow-
up.
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Background: The main purpose of this study was to assess on the large patient
population the performance and clinical outcome of Misago SX nitinol stent in the
treatment of superficial femoral (SF) or popliteal arteries
Methods: MISAGO 2 registry enrolled 744 patients undergoing percutaneous
intervention of stenotic or occluded lesions in SF or popliteal arteries in 76 centres
across Europe. In total 754 lesions were treated with 916 stents. All clinical events are
independently adjudicated. The primary endpoint was absence of clinically driven
target lesion revascularization at 6 and 12 months.
Results: Patients (67% male) were 69±10 years old, 68% had hypertension, 60% were
smokers and 35% diabetes. Average lesion length was 64±38 mm, 38% lesions were
totally occluded and 64% massively or moderately calcified. Technical and procedural
success rates were 99%. 12-Month follow-up done on more than 90% of the subjects
treated at baseline (655) showed freedom from target lesion revascularization of 89.6%
and primary patency rate of 87.6%. Total number of subjects with any adverse event
(any death, amputation, revascularization, vascular, bleeding and cerebrovascular
event) was 14.8%. Ankle brachial index increased for more than 0.1 in 76% of the
subjects, and Rutherford index improved in 87% of the subjects. There was no
clinically relevant (grade 3&4 out of 4)stent fracture reported in the study. Overall
fracture rate was 3.1.
Conclusion: Results of the large multicentre MISAGO 2 registry that evaluated
Misago RX system in SFA and popliteal arteries showed excellent TLR and primary
patency rate at one year. Low fracture rate observed was not related with any of TLR
occurred.
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Background: Although endovascular therapy (EVT) has been shown efficacious in
patients with critical limb ischemia (CLI), EVT is not always successful in limb
salvage. We sought to investigate the factors related to the failure of limb salvage
following EVT.
Methods: Consecutive 358 legs from 307 CLI patients (Rutherford 4 to 6) who
underwent EVT were enrolled between April, 2003 and April, 2009. Primary endpoint
comprised amputation or bypass surgery. Patients were followed for 20 +/- 16 months.
Logistic regression analysis was performed to explore the independent determinants
of the prognosis of the legs.
Results: Initial success rate was 86%. Bypass surgery or amputation was done in 78
limbs. Age, ankle brachial index, hypertension, Rutherford class and distal blood flow
below the ankle were chosen as independent variables by single regression analysis.
Among these, distal blood flow was chosen as the strongest independent predictor
associated with the prognosis of the legs by multivariate analysis (Table).
Conclusion: Poor flow below the ankle was the strongest factor related to the failure
of limb salvage following EVT.
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Background: Non-traumatic lower extremity amputation is associated with significant
morbidity and mortality. With the emergence of newer improved therapies for
revascularization, the use of imaging to identify treatable disease prior to amputation
is not known.
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